ビマトプロスト

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H302：飲み込むと有害

• 注意書き

  P201：使用前に取扱説明書を入手すること。

  P308+P313：暴露または暴露の懸念がある場合：医師の診断/手当てを 受けること。

ビマトプロスト 価格

ビマトプロスト 化学特性,用途語,生産方法

• 外観

  白色～わずかにうすい黄色, 結晶性粉末～粉末

• 溶解性

  エタノール及びメタノールに極めて溶けやすく、水及び酢酸エチルに溶けにくい。

• 用途

  プロスタマイド受容体（PM 受容体）に作用し、眼房水の排出を促進する ことで、眼圧低下作用を示します。

• 効能

  抗緑内障薬, 睫毛発毛薬

• 商品名

  グラッシュビスタ (アラガン・ジャパン); グラッシュビスタ (アラガン・ジャパン); ルミガン (千寿製薬)

• 説明

  Bimatoprost was first introduced in the US and Brazil as Lumigan?, an ophthalmic solution (0.03%) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, a proven risk of glaucomatous visual field loss. Bitamoprost is a new agent belonging to the PGF_2α analog class of prostamides launched in this indication after latanoprost, the most efficaceous topical medication currently available. This synthetic fatty acid amide can be prepared by esterification of 17- phenyl-18,19,20-trinorprostaglandin F_2α followed by ethylamidation. Bimatoprost, as related prostamides, is devoid of typical activities associated with PGF2,, analogs; it exhibits a unique pharmacological profile in contracting the feline iris sphincter with an EC₅₀ of 34 nM without interacting with any known prostanoid receptors. Thus it mimics the action of endogenous prostamides on specific receptors that lower IOP by increasing aqueous humor outflow through both pressure-insensitive and pressure-sensitive pathways without reducing humor formation. In a 3-month controlled clinical trial of efficacy and safety in patients with elevated IOP, bimatoprost demonstrated lower mean intraocular pressures at every time point throughout the study, as well as a good tolerance and systemic safety profile compared to latanoprost.

• 化学的特性

  Crystalline Solid

• 使用

  Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. It reduces intraocular pressure (IOP) by increasing the outflow of aqueous fluid from the eyes. It ha

• 一般的な説明

  Bimatoprost (Lumigan) is supplied as a sterile 0.03%ophthalmic solution in 2.5- and 5.0-mL sizes. The recommendeddosage of bimatoprost is limited to one drop intothe affected eye once daily in the evening. Increased usagemay decrease its beneficial effect. If used concurrently withother IOP-lowering drugs, a waiting period of 5 minutesshould separate administrations.

ビマトプロスト 上流と下流の製品情報

ビマトプロスト 生産企業

Global(573)Suppliers

ビマトプロスト スペクトルデータ(¹HNMR)

155206-00-1, ビマトプロスト キーワード